A Phase 3 interventional study of Placebo and RSVPreF3 OA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 277 sites in 17 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one has the largest enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 3rd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2021.
This study's enrollment of 26,675 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one has the largest enrollment, is one of 6 that started in 2021, is one of 21 in phase 3, and was the 19th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.
Dose 1 Period will be conducted in 2 parts: Part 1: Participants in RSVPreF3 groups will receive lots 1, 2 and 3 of the investigational vaccine before Season 1. Part 2: Will be initiated when the vaccine lots in part 1 are exhausted at the study sites and participants in RSVPreF3 group will receive lot 4 of the investigational vaccine before Season 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: In case of physical incapacity that would preclude the self-completion of the diary cards and/or questionnaires, either site staff can assist the participant (for activities performed during site visits) or the participant may assign a caregiver to assist him/her with this activity (for activities performed at home or in the LTCF). However, at no time, the site staff or caregiver will evaluate the participant's health status while answering diaries and/or questionnaires or make decisions on behalf of the participant
Exclusion Criteria:
Medical conditions
Note: If deemed necessary for clinical evaluation, the investigator can use tools such as (MMSE), Mini-Cog or Montreal Cognitive Assessment (MoCA) to determine cognition levels of the participant.
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Planned move during the study period that will prohibit participating in the trial until study end. This includes:
Planned leave or holiday of 4 consecutive weeks or more during the RSV seasons* covered by the study, that would prohibit the reporting of ARI cases and attendance to ARI visit.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.
Biological: RSVPreF3 OA vaccine
Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.
Biological: Placebo
Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.
RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine
First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.
Time frame: From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
Time frame: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the Northern Hemisphere [NH] (assessed approximately over 2 and 3 years in NH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine
Efficacy of annual revaccination doses of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
Time frame: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the NH (assessed approximately over 2 and 3 years in NH)
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose
Efficacy of a single dose and 1 annual revaccination dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine
Time frame: From Day 15 post-vaccination up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, in the following age categories: greater than or equal to (≥) 65 years of age (YOA), ≥70 YOA and ≥80 YOA.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by RSV season as follows: VE after each season includes the first occurrence of episodes reported from Day 15 post vaccination at first season, and for the next seasons, excluding analysis of participants who already reported a case in the previous season. The RSV season may be extended based on epidemiology data.
Time frame: From Day 15 post first dose or start of the RSV season to the first occurrence of RSV-confirmed LRTD at each RSV season (assessed approximately over 7 months at each season [Seasons 1 and 2 in SH, Seasons 1, 2 and 3 in NH])
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by years after vaccination as follows: VE at each year includes the first occurrence of episodes reported from Day 14 post vaccination at first year, and for the next years, excluding analysis of participants who already reported a case in the previous year.
Time frame: From Day 15 post first dose and each revaccination dose up to next dose or end of study (assessed approximately over a year after each vaccination [at Year 1, Year 2 and Year 3])
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Time frame: From Day 15 post first dose to the first occurrence of RSV LRTD (assessed approximately over 3 years in the NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities using Charlson Comorbidity Index. Low/medium Risk = Participants with co-morbidity score at baseline less than or equal to 3 (Charlson Index); High Risk = Participants with co-morbidity score at baseline greater than 3 (Charlson Index).
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities of interest divided into 2: cardiorespiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or pulmonary disease, and endocrinometabolic conditions such as diabetes mellitus type 1 or 2, chronic heart failure and advanced liver or renal disease.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and /or B associated LRTD episode according to the case definition, by baseline frailty status of frail, pre-frail and fit. Frail = Participants with a walking speed of less than (\<) 0.4 meters per second (m/s) or who were not able to perform the test; Pre-Frail = Participants with a walking speed between 0.4-0.99 m/s; Fit = Participants with a walking speed of ≥1 m/s.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated severe LRTD episode. Case definition for RSV-confirmed severe LRTD: An RT-PCR confirmed case of RSV-associated severe LRTD is characterized by presence of lower respiratory signs or an LRTD episode assessed as severe by the investigator (Severe LRTD case definition 1) or presence of an LRTD with need for oxygen supplementation or need for positive airway pressure therapy or need for other types of mechanical ventilation (Severe LRTD case definition 2) and with at least one RSV positive swab detected by RT-PCR.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV confirmed A and/or B associated ARI episode. A case of RT-PCR confirmed RSV-associated ARI is characterized by the presence of respiratory symptoms/signs for at least 24 hours OR respiratory symptom/sign + systemic symptom/sign for at least 24 hours with at least one RSV-positive swab detected by RT-PCR.
Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against any ARI and any LRTD.
Time frame: From Day 15 post first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV infection was confirmed by RT-PCR.
Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system.
Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV infection was confirmed by RT-PCR.
Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
RSV infection was confirmed by RT-PCR.
Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Maximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
For this outcome measure, the Health Related -Quality of life (HR-QOL) score is measured by Flu-PRO questionnaire version 2.0. The Flu-PRO is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The objective of this outcome measure was to present data only for chest/respiratory system after a single dose and after annual revaccination. The FLU-PRO score was computed as the mean score across questionaire items for chest/respiratory body system, with the scores ranging from 0 (symptom free) to 4 (very severe symptoms).
Time frame: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])
Least Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
The Flu-PRO questionnaire version 2.0 is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The FLU-PRO total score was computed as the mean score across all 32 items of the questionaire for all 6 body systems, with the total scores ranging from 0 (symptom free) to 4 (very severe symptoms).
Time frame: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])
EuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
The EQ-5D is a general health utility questionnaire with health states, defined through 5 dimensions- mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. A participant who responds 1 (no problem/no symptom) to all 5 items has a profile "11111" and similarly a participant who responds 3 (the highest level of difficulty or symptom) to all items has a profile "33333". The health states indicated in these 5 dimensions are converted and presented as a single mean index value as recommended by EuroQol group, where values range from 0 (worst) to 1 (full health).
Time frame: At the ARI visit (assessed from Day 15 post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)
Least Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
SF-12 is a health survey with 12 questions, covering 8 domains- physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Summary scores are computed from these domains for the physical and mental component. The total score of the SF-12 questionnaire is evaluated on a scale from 0 to 100, with a higher score indicating a better perceived health-related quality of life.
Time frame: At the ARI visit (assessed from one-month post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
The duration in days of RT-PCR confirmed RSV A and/or B ARI and LRTD episodes are described.
Time frame: From Day 15 post first dose to end of Season 1, from 15 days post-second dose administration to end of Season 2, and from start to end of Season 3 [all seasons summing approximately 3 years in NH and 2.5-3 years in SH]
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Time frame: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Time frame: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
Time frame: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Time frame: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Time frame: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
Time frame: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
RSV A and/or B ARI and LRTD episodes were assessed as "mild", "moderate" or "severe" by the investigator after the single dose and after annual revaccination. Mild = an ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate = an ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe = an ARI/LRTD episode which prevents normal, everyday activities.
Time frame: Assessed during the study period (approximately 3 years for NH and 2.5-3 years for SH)
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
The RSVPreF3 IgG antibody concentrations are expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL).
Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
RSV A Neutralizing Antibody Titers
The RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs).
Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
RSV B Neutralizing Antibody Titers
RSV B neutralizing antibodies are expressed as GMTs.
Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed administration site events include pain, erythema and swelling.
Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed solicited systemic events include arthralgia, fatigue, fever, headache and myalgia. Fever is defined as a temperature ≥ 38.0°C by any route. Grade 3 fever is defined as temperature \>39°C by any route.
Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Number of Days With Solicited Administration Site Adverse Events
Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Number of Days With Solicited Systemic Adverse Events
Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Number of Participants With Any Unsolicited AEs
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside of the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any= occurrence of the event regardless of intensity grade or relation to the study vaccination.
Time frame: During the 30-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH)
Number of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of any SAE regardless of intensity grade or relation to study vaccination.
Time frame: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])
Number of Participants With Potential Immune Mediated Diseases (pIMDs)
pIMDs aredefined as a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any= occurrence of any pIMD regardless of intensity grade or relation to the study vaccination.
Time frame: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])
Number of Participants With Related SAEs
Related SAEs that occur throughout the study are assessed. Related SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator.
Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Participants With Fatal SAEs
Fatal SAEs that occur throughout the study are assessed. Fatal SAEs= Any SAEs leading to deaths.
Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Number of Participants With Related pIMDs
Related pIMD = pIMD assessed by the investigator as related to the study vaccination.
Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
| Milestone | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Started | 12469 | 12503 |
| Rsv 1 dose | 6226 | 0 |
| Rsv annual | 6243 | 0 |
| Completed | 9365 | 9361 |
| Not completed | 3104 | 3142 |
| Withdrew: Adverse event | 442 | 441 |
| Withdrew: Lost to follow-up | 448 | 465 |
| Withdrew: Consent withdrawal, not due to a (s)ae | 1715 | 1726 |
| Withdrew: Migrated/moved from the study area | 201 | 184 |
| Withdrew: Other | 298 | 326 |
First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine | 7 | 40 |
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Season 2 (NH) | 30 | 139 |
| Season 3 (NH) | 48 | 215 |
Efficacy of annual revaccination doses of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Season 2 (NH) | 30 | 139 |
| Season 3 (NH) | 38 | 192 |
Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV-A LRTD | 14 | 80 |
| RT-PCR-confirmed RSV-B LRTD | 34 | 135 |
Efficacy of a single dose and 1 annual revaccination dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV-A LRTD | 17 | 65 |
| RT-PCR-confirmed RSV-B LRTD | 21 | 127 |
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine | 53 | 65 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, in the following age categories: greater than or equal to (≥) 65 years of age (YOA), ≥70 YOA and ≥80 YOA.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV LRTD (Single dose), >=65 YOA | 38 | 156 |
| RT-PCR-confirmed RSV LRTD (Single dose), >=70 YOA | 20 | 98 |
| RT-PCR-confirmed RSV LRTD (Single dose), >=80 YOA, | 5 | 13 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), >=65 YOA | 28 | 137 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), >=70 YOA | 19 | 87 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), >=80 YOA | 5 | 12 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by RSV season as follows: VE after each season includes the first occurrence of episodes reported from Day 15 post vaccination at first season, and for the next seasons, excluding analysis of participants who already reported a case in the previous season. The RSV season may be extended based on epidemiology data.
| Participants | RSVPreF3 Group | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|---|
| RT-PCR-confirmed RSV LRTD, Season 1 | 7 | 36 | — | — |
| RT-PCR-confirmed RSV LRTD, Season 2 (Single dose) | — | 98 | 19 | — |
| RT-PCR-confirmed RSV LRTD, Season 2 (Annual revaccination) | — | 98 | — | 22 |
| RT-PCR-confirmed RSV LRTD, Season 3 (Single dose) | — | 60 | 16 | — |
| RT-PCR-confirmed RSV LRTD, Season 3 (Annual revaccination) | — | 37 | — | 6 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by years after vaccination as follows: VE at each year includes the first occurrence of episodes reported from Day 14 post vaccination at first year, and for the next years, excluding analysis of participants who already reported a case in the previous year.
| Participants | RSVPreF3 Group | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|---|
| RT-PCR-confirmed RSV LRTD, Year 1 | 10 | 47 | — | — |
| RT-PCR-confirmed RSV LRTD, Year 2 (Single dose) | — | 106 | 22 | — |
| RT-PCR-confirmed RSV LRTD, Year 2 (Annual revaccination) | — | 106 | — | 22 |
| RT-PCR-confirmed RSV LRTD, Year 3 (Single dose) | — | 61 | 16 | — |
| RT-PCR-confirmed RSV LRTD, Year 3 (Annual revaccination) | — | 38 | — | 6 |
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Season 1 | 10 | 47 |
| Season 2 (Single dose) | 32 | 154 |
| Season 2 (Annual revaccination) | 32 | 154 |
| Season 3 (NH) (Single dose) | 48 | 215 |
| Season 3 (NH) (Annual revaccination) | 38 | 192 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities using Charlson Comorbidity Index. Low/medium Risk = Participants with co-morbidity score at baseline less than or equal to 3 (Charlson Index); High Risk = Participants with co-morbidity score at baseline greater than 3 (Charlson Index).
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV LRTD (Single dose), Low/Medium risk | 24 | 119 |
| RT-PCR-confirmed RSV LRTD (Single dose), High risk | 24 | 96 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), Low/Medium risk | 18 | 108 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), High risk | 20 | 84 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities of interest divided into 2: cardiorespiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or pulmonary disease, and endocrinometabolic conditions such as diabetes mellitus type 1 or 2, chronic heart failure and advanced liver or renal disease.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Confirmed RSV LRTD (Single dose), No pre-existing comorbidity of interest | 23 | 99 |
| Confirmed RSV LRTD (Single dose), At least 1 pre-existing comorbidity of interest | 25 | 116 |
| Confirmed RSV LRTD (Single dose), At least 1 pre-existing Cardiorespiratory condition | 17 | 85 |
| Confirmed RSV LRTD (Single dose), At least 1 pre-existing Endocrinometabolic condition | 12 | 55 |
| Confirmed RSV LRTD (Annual revaccination), No pre-existing comorbidity of interest | 20 | 91 |
| Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing comorbidity of interest | 18 | 101 |
| Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Cardiorespiratory condition | 11 | 73 |
| Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Endocrinometabolic condition | 9 | 49 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and /or B associated LRTD episode according to the case definition, by baseline frailty status of frail, pre-frail and fit. Frail = Participants with a walking speed of less than (\<) 0.4 meters per second (m/s) or who were not able to perform the test; Pre-Frail = Participants with a walking speed between 0.4-0.99 m/s; Fit = Participants with a walking speed of ≥1 m/s.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV LRTD (Single dose), Frail | 2 | 1 |
| RT-PCR-confirmed RSV LRTD (Single dose), Pre-Frail | 12 | 67 |
| RT-PCR-confirmed RSV LRTD (Single dose), Fit | 34 | 145 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), Frail | 1 | 1 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), Pre-Frail | 10 | 63 |
| RT-PCR-confirmed RSV LRTD (Annual revaccination), Fit | 27 | 126 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated severe LRTD episode. Case definition for RSV-confirmed severe LRTD: An RT-PCR confirmed case of RSV-associated severe LRTD is characterized by presence of lower respiratory signs or an LRTD episode assessed as severe by the investigator (Severe LRTD case definition 1) or presence of an LRTD with need for oxygen supplementation or need for positive airway pressure therapy or need for other types of mechanical ventilation (Severe LRTD case definition 2) and with at least one RSV positive swab detected by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV severe LRTD (Single dose), Any | 15 | 75 |
| RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 1: Clinical symptomology | 15 | 75 |
| RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 2: Supportive therapy | 2 | 7 |
| RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Any | 9 | 67 |
| RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 1: Clinical symptomology | 9 | 67 |
| RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 2: Supportive therapy | 0 | 6 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV confirmed A and/or B associated ARI episode. A case of RT-PCR confirmed RSV-associated ARI is characterized by the presence of respiratory symptoms/signs for at least 24 hours OR respiratory symptom/sign + systemic symptom/sign for at least 24 hours with at least one RSV-positive swab detected by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RT-PCR-confirmed RSV ARI (Single dose) | 131 | 428 |
| RT-PCR-confirmed RSV ARI (Annual revaccination) | 103 | 385 |
Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against any ARI and any LRTD.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Any ARI (Single dose) | 4858 | 6096 |
| Any ARI (Annual revaccination) | 4731 | 5914 |
| Any LRTD (Single dose) | 12450 | 3352 |
| Any LRTD (Annual revaccination) | 2308 | 3210 |
RSV infection was confirmed by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| RSV respiratory disease (Single dose), during season | 2 | 4 |
| RSV respiratory disease or related complication (Single dose), during season | 2 | 4 |
| RSV respiratory disease (Annual revaccination),during season | 0 | 4 |
| RSV respiratory disease or related complication (Annual revaccination), during season | 0 | 4 |
| RSV respiratory disease (Single dose), up to end of study | 2 | 6 |
| RSV respiratory disease or related complication (Single dose), up to end of study | 2 | 6 |
| RSV respiratory disease (Annual revaccination), up to end of study | 0 | 6 |
| RSV respiratory disease or related complication (Annual revaccination), up to end of study | 0 | 6 |
A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Any respiratory disease (Single dose), during seasons | 121 | 174 |
| Any respiratory disease or related complication (Single dose), during seasons | 131 | 180 |
| Any respiratory disease (Annual revaccination), during seasons | 114 | 163 |
| Any respiratory disease or related complication (Annual revaccination), during seasons | 119 | 169 |
| Any respiratory disease (Single dose), up to end of study | 167 | 221 |
| Any respiratory disease or related complication (Single dose), up to end of study | 179 | 230 |
| Any respiratory disease (Annual revaccination), up to end of study | 163 | 208 |
| Any respiratory disease or related complication (Annual revaccination), up to end of study | 171 | 217 |
RSV infection was confirmed by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Related to RT-PCR-confirmed RSV ARI (Single dose), up to end of study | 12 | 50 |
| Related to RT-PCR-confirmed RSV ARI (Annual revaccination), up to end of study | 11 | 46 |
| Related to RT-PCR-confirmed RSV ARI (Single dose), during season | 9 | 43 |
| Related to RT-PCR-confirmed RSV ARI (Annual revaccination), during season | 9 | 39 |
RSV infection was confirmed by RT-PCR.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Complications related to any ARI (Single dose), during season | 438 | 695 |
| Complications related to any ARI (Annual revaccination), during season | 417 | 660 |
| Complications related to any ARI (Single dose), up to end of study | 620 | 863 |
| Complications related to any ARI (Annual revaccination), up to end of study | 579 | 823 |
For this outcome measure, the Health Related -Quality of life (HR-QOL) score is measured by Flu-PRO questionnaire version 2.0. The Flu-PRO is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The objective of this outcome measure was to present data only for chest/respiratory system after a single dose and after annual revaccination. The FLU-PRO score was computed as the mean score across questionaire items for chest/respiratory body system, with the scores ranging from 0 (symptom free) to 4 (very severe symptoms).
| Scores on a scale | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Chest / Respiratory (Single dose) | 1.60 ± 0.89 | 1.97 ± 0.88 |
| Chest / Respiratory (Annual revaccination) | 1.50 ± 0.87 | 1.96 ± 0.89 |
The Flu-PRO questionnaire version 2.0 is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The FLU-PRO total score was computed as the mean score across all 32 items of the questionaire for all 6 body systems, with the total scores ranging from 0 (symptom free) to 4 (very severe symptoms).
| Scores on a scale | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Day 1 to Day 7 (Single dose) | 0.85 ± 0.07 | 0.92 ± 0.06 |
| Day 1 to Day 7 (Annual revaccination) | 0.81 ± 0.07 | 0.90 ± 0.06 |
The EQ-5D is a general health utility questionnaire with health states, defined through 5 dimensions- mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. A participant who responds 1 (no problem/no symptom) to all 5 items has a profile "11111" and similarly a participant who responds 3 (the highest level of difficulty or symptom) to all items has a profile "33333". The health states indicated in these 5 dimensions are converted and presented as a single mean index value as recommended by EuroQol group, where values range from 0 (worst) to 1 (full health).
| Scores on a scale | RSVPreF3 Group | Placebo Group |
|---|---|---|
| At ARI visit (Single dose) | 0.8164 ± 0.0258 | 0.7886 ± 0.0197 |
| At ARI visit (Annual revaccination) | 0.8377 ± 0.0259 | 0.7966 ± 0.0197 |
SF-12 is a health survey with 12 questions, covering 8 domains- physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Summary scores are computed from these domains for the physical and mental component. The total score of the SF-12 questionnaire is evaluated on a scale from 0 to 100, with a higher score indicating a better perceived health-related quality of life.
| Scores on a scale | RSVPreF3 Group | Placebo Group |
|---|---|---|
| At ARI visit (Single dose) | 59.43 ± 4.07 | 57.51 ± 3.15 |
| At ARI visit (Annual revaccination) | 63.65 ± 4.15 | 59.02 ± 3.18 |
The duration in days of RT-PCR confirmed RSV A and/or B ARI and LRTD episodes are described.
| Days | RSVPreF3 Group | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|---|
| RT-PCR-confirmed RSV ARI, Season 1 | 12.0 (8.0 to 19.0) | 15.0 (11.0 to 22.0) | — | — |
| RT-PCR-confirmed RSV LRTD, Season 1 | 15.5 (8.0 to 19.0) | 20.0 (15.0 to 27.0) | — | — |
| RT-PCR-confirmed RSV ARI, Season 2 | — | 16.0 (12.0 to 24.0) | 14.0 (10.0 to 23.0) | 13.0 (9.0 to 18.0) |
| RT-PCR-confirmed RSV LRTD, Season 2 | — | 16.0 (13.0 to 24.0) | 17.0 (10.0 to 28.0) | 14.0 (9.0 to 23.0) |
| RT-PCR-confirmed RSV ARI, Season 3 | — | 16.0 (14.0 to 22.0) | 16.0 (13.0 to 24.0) | 10.0 (7.0 to 21.0) |
| RT-PCR-confirmed RSV LRTD, Season 3 | — | 17.5 (14.5 to 26.0) | 16.5 (15.0 to 24.5) | 12.0 (7.0 to 21.0) |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Nasal Congestion | 28 | 83 |
| Rhinorrhea | 32 | 93 |
| Sore Throat | 26 | 76 |
| Cough (new or increased) | 36 | 101 |
| Sputum (new or increased) | 20 | 75 |
| Shortness of breath or dyspnea (new or increased) | 7 | 35 |
| Wheezing (new or increased) | 5 | 25 |
| Crackles | 1 | 6 |
| Rhonchi | 1 | 13 |
| Respiratory rate ≥20 breaths/minute | 3 | 11 |
| Low or decreased oxygen saturation | 1 | 9 |
| Fever | 2 | 8 |
| Feverishness | 8 | 24 |
| Fatigue | 22 | 67 |
| Body aches | 12 | 40 |
| Headache | 20 | 55 |
| Decreased appetite | 13 | 42 |
| Need for oxygen supplementation | 0 | 4 |
| Need for positive airway pressure therapy | 0 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 |
| Other symptoms or signs | 7 | 22 |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Nasal Congestion | 162 | 43 | 31 |
| Rhinorrhea | 186 | 52 | 39 |
| Sore Throat | 147 | 43 | 33 |
| Cough (new or increased) | 201 | 55 | 41 |
| Sputum (new or increased) | 150 | 39 | 29 |
| Shortness of breath or dyspnea (new or increased) | 79 | 17 | 19 |
| Wheezing (new or increased) | 56 | 15 | 10 |
| Crackles | 19 | 2 | 3 |
| Rhonchi | 32 | 8 | 7 |
| Respiratory rate ≥20 breaths/minute | 21 | 5 | 0 |
| Low or decreased oxygen saturation | 8 | 1 | 4 |
| Fever | 21 | 5 | 7 |
| Feverishness | 64 | 13 | 15 |
| Fatigue | 145 | 34 | 33 |
| Body aches | 91 | 27 | 24 |
| Headache | 124 | 36 | 28 |
| Decreased appetite | 85 | 20 | 18 |
| Need for oxygen supplementation | 1 | 1 | 0 |
| Need for positive airway pressure therapy | 0 | 1 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 | 0 |
| Other symptoms or signs | 48 | 12 | 14 |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Nasal Congestion | 101 | 25 | 15 |
| Rhinorrhea | 98 | 26 | 17 |
| Sore Throat | 76 | 17 | 14 |
| Cough (new or increased) | 111 | 27 | 18 |
| Sputum (new or increased) | 86 | 23 | 10 |
| Shortness of breath or dyspnea (new or increased) | 42 | 10 | 5 |
| Wheezing (new or increased) | 32 | 6 | 3 |
| Crackles | 10 | 2 | 0 |
| Rhonchi | 16 | 8 | 2 |
| Respiratory rate ≥20 breaths/minute | 9 | 3 | 0 |
| Low or decreased oxygen saturation | 11 | 1 | 3 |
| Fever | 10 | 2 | 0 |
| Feverishness | 32 | 14 | 6 |
| Fatigue | 85 | 21 | 15 |
| Body aches | 56 | 16 | 10 |
| Headache | 66 | 16 | 12 |
| Decreased appetite | 52 | 13 | 12 |
| Need for oxygen supplementation | 0 | 1 | 0 |
| Need for positive airway pressure therapy | 0 | 0 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 | 0 |
| Other symptoms or signs | 35 | 6 | 9 |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Nasal Congestion | 7 | 38 |
| Rhinorrhea | 9 | 38 |
| Sore Throat | 5 | 33 |
| Cough (new or increased) | 10 | 47 |
| Sputum (new or increased) | 8 | 36 |
| Shortness of breath or dyspnea (new or increased) | 4 | 29 |
| Wheezing (new or increased) | 5 | 24 |
| Crackles | 1 | 6 |
| Rhonchi | 0 | 13 |
| Respiratory rate ≥20 breaths/minute | 3 | 10 |
| Low or decreased oxygen saturation | 1 | 8 |
| Fever | 1 | 8 |
| Feverishness | 2 | 16 |
| Fatigue | 6 | 37 |
| Body aches | 5 | 22 |
| Headache | 4 | 27 |
| Decreased appetite | 7 | 26 |
| Need for oxygen supplementation | 0 | 4 |
| Need for positive airway pressure therapy | 0 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 |
| Other symptoms or signs | 2 | 12 |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Nasal Congestion | 90 | 20 | 15 |
| Rhinorrhea | 96 | 20 | 19 |
| Sore Throat | 79 | 17 | 15 |
| Cough (new or increased) | 106 | 21 | 20 |
| Sputum (new or increased) | 95 | 19 | 17 |
| Shortness of breath or dyspnea (new or increased) | 72 | 14 | 13 |
| Wheezing (new or increased) | 56 | 15 | 10 |
| Crackles | 19 | 2 | 3 |
| Rhonchi | 31 | 5 | 7 |
| Respiratory rate ≥20 breaths/minute | 21 | 5 | 0 |
| Low or decreased oxygen saturation | 8 | 1 | 4 |
| Fever | 13 | 3 | 3 |
| Feverishness | 44 | 7 | 8 |
| Fatigue | 86 | 16 | 15 |
| Body aches | 53 | 15 | 11 |
| Headache | 70 | 17 | 14 |
| Decreased appetite | 47 | 13 | 11 |
| Need for oxygen supplementation | 1 | 1 | 0 |
| Need for positive airway pressure therapy | 0 | 1 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 | 0 |
| Other symptoms or signs | 28 | 3 | 5 |
RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Nasal Congestion | 54 | 13 | 4 |
| Rhinorrhea | 50 | 14 | 4 |
| Sore Throat | 42 | 9 | 5 |
| Cough (new or increased) | 60 | 15 | 6 |
| Sputum (new or increased) | 53 | 14 | 5 |
| Shortness of breath or dyspnea (new or increased) | 38 | 9 | 4 |
| Wheezing (new or increased) | 32 | 5 | 3 |
| Crackles | 10 | 2 | 0 |
| Rhonchi | 16 | 8 | 2 |
| Respiratory rate ≥20 breaths/minute | 9 | 3 | 0 |
| Low or decreased oxygen saturation | 11 | 1 | 3 |
| Fever | 6 | 0 | 0 |
| Feverishness | 22 | 8 | 3 |
| Fatigue | 49 | 13 | 6 |
| Body aches | 39 | 10 | 5 |
| Headache | 41 | 10 | 5 |
| Decreased appetite | 33 | 11 | 3 |
| Need for oxygen supplementation | 0 | 1 | 0 |
| Need for positive airway pressure therapy | 0 | 0 | 0 |
| Need of other types of mechanical ventilation | 0 | 0 | 0 |
| Other symptoms or signs | 22 | 4 | 3 |
RSV A and/or B ARI and LRTD episodes were assessed as "mild", "moderate" or "severe" by the investigator after the single dose and after annual revaccination. Mild = an ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate = an ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe = an ARI/LRTD episode which prevents normal, everyday activities.
| Participants | RSVPreF3 Group | Placebo Group |
|---|---|---|
| Mild (Single dose) | 16 | 49 |
| Moderate (Single dose) | 29 | 138 |
| Severe (Single dose) | 3 | 28 |
| Mild (Annual revaccination) | 15 | 48 |
| Moderate (Annual revaccination) | 23 | 120 |
| Severe (Annual revaccination) | 0 | 24 |
The RSVPreF3 IgG antibody concentrations are expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL).
| EU/mL | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Pre-dose 1 at day 1 | 7090.2 (6783.4 to 7410.9) | 6956.5 (6505.2 to 7439.2) | 7101.1 (6640.7 to 7593.4) |
| Post-dose 1 at day 31 | 7053.2 (6732.0 to 7389.8) | 89361.9 (83409.6 to 95738.9) | 93769.5 (87896.6 to 100034.8) |
| Pre-Season 2 | 7594.8 (7203.9 to 8007.0) | 24103.6 (22366.8 to 25975.3) | 24523.8 (22748.7 to 26437.4) |
| Pre-Season 3 | 8436.6 (7927.3 to 8978.7) | 21255.0 (19587.7 to 23064.2) | 28925.3 (26928.0 to 31070.7) |
The RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs).
| Titers | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Pre-dose 1 at day 1 | 933.5 (881.8 to 988.4) | 899.8 (829.1 to 976.5) | 929.3 (852.6 to 1013.0) |
| Post-dose 1 at day 31 | 880.8 (828.9 to 935.9) | 8915.5 (8080.6 to 9836.8) | 9652.4 (8727.5 to 10675.3) |
| Pre-Season 2 | 865.8 (809.6 to 925.9) | 2535.9 (2284.7 to 2814.8) | 2918.4 (2594.5 to 3282.9) |
| Pre-Season 3 | 977.9 (905.5 to 1056.0) | 2049.7 (1841.0 to 2282.1) | 2996.1 (2665.3 to 3368.1) |
RSV B neutralizing antibodies are expressed as GMTs.
| Titers | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Pre-dose 1 at day 1 | 1249.7 (1179.1 to 1324.5) | 1189.9 (1097.4 to 1290.2) | 1187.2 (1096.7 to 1285.2) |
| Post-dose 1 at day 31 | 1262.4 (1183.8 to 1346.2) | 9928.9 (9103.7 to 10829.0) | 10253.4 (9362.7 to 11228.9) |
| Pre-Season 2 | 1229.7 (1149.9 to 1315.1) | 2955.5 (2677.0 to 3262.9) | 2979.2 (2692.2 to 3296.9) |
| Pre-Season 3 | 946.8 (873.5 to 1026.3) | 2054.5 (1829.9 to 2306.5) | 2515.3 (2249.9 to 2812.0) |
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed administration site events include pain, erythema and swelling.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Erythema, Dose 1, Any | 10 | 41 | 30 |
| Erythema, Dose 1, Grade 3 | 0 | 0 | 2 |
| Erythema, Dose 2, Any | 1 | 1 | 31 |
| Erythema , Dose 2, Grade 3 | 0 | 0 | 3 |
| Erythema, Dose 3 (NH), Any | 0 | 0 | 2 |
| Erythema, Dose 3 (NH), Grade 3 | 0 | 0 | 1 |
| Pain, Dose 1, Any | 81 | 267 | 268 |
| Pain, Dose 1, Grade 3 | 0 | 6 | 3 |
| Pain, Dose 2, Any | 51 | 30 | 169 |
| Pain, Dose 2, Grade 3 | 0 | 0 | 2 |
| Pain, Dose 3 (NH), Any | 7 | 3 | 25 |
| Pain, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
| Swelling, Dose 1, Any | 7 | 25 | 28 |
| Swelling, Dose 1, Grade 3 | 0 | 0 | 2 |
| Swelling, Dose 2, Any | 2 | 0 | 23 |
| Swelling, Dose 2, Grade 3 | 0 | 0 | 6 |
| Swelling, Dose 3 (NH), Any | 0 | 1 | 2 |
| Swelling, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed solicited systemic events include arthralgia, fatigue, fever, headache and myalgia. Fever is defined as a temperature ≥ 38.0°C by any route. Grade 3 fever is defined as temperature \>39°C by any route.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Arthralgia, Dose 1, Any | 56 | 74 | 84 |
| Arthralgia, Dose 1, Grade 3 | 5 | 5 | 6 |
| Arthralgia, Dose 2, Any | 48 | 20 | 55 |
| Arthralgia, Dose 2, Grade 3 | 2 | 0 | 2 |
| Arthralgia, Dose 3 (NH), Any | 5 | 2 | 5 |
| Arthralgia, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
| Fatigue, Dose 1, Any | 141 | 143 | 153 |
| Fatigue, Dose 1, Grade 3 | 4 | 6 | 9 |
| Fatigue, Dose 2, Any | 80 | 44 | 98 |
| Fatigue, Dose 2, Grade 3 | 7 | 2 | 3 |
| Fatigue, Dose 3 (NH), Any | 12 | 8 | 9 |
| Fatigue, Dose 3 (NH), Grade 3 | 0 | 1 | 0 |
| Fever, Dose 1, Any | 3 | 14 | 4 |
| Fever, Dose 1, Grade 3 | 1 | 1 | 0 |
| Fever, Dose 2, Any | 4 | 1 | 6 |
| Fever, Dose 2, Grade 3 | 2 | 0 | 0 |
| Fever, Dose 3 (NH), Any | 1 | 0 | 0 |
| Fever, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
| Headache, Dose 1, Any | 111 | 116 | 123 |
| Headache, Dose 1, Grade 3 | 0 | 6 | 5 |
| Headache, Dose 2, Any | 60 | 41 | 73 |
| Headache, Dose 2, Grade 3 | 4 | 1 | 2 |
| Headache, Dose 3 (NH), Any | 9 | 6 | 5 |
| Headache, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
| Myalgia, Dose 1, Any | 72 | 127 | 128 |
| Myalgia, Dose 1, Grade 3 | 3 | 5 | 7 |
| Myalgia, Dose 2, Any | 52 | 20 | 82 |
| Myalgia, Dose 2, Grade 3 | 3 | 0 | 3 |
| Myalgia, Dose 3 (NH), Any | 5 | 3 | 7 |
| Myalgia, Dose 3 (NH), Grade 3 | 0 | 0 | 0 |
| Days | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Erythema, Dose 1 | 4.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| Erythema, Dose 2 | 4.0 (4.0 to 4.0) | 2.0 (2.0 to 2.0) | 3.0 (2.0 to 3.0) |
| Erythema, Dose 3 (NH) | — | — | 3.0 (2.0 to 4.0) |
| Pain, Dose 1 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) | 2.0 (2.0 to 3.0) |
| Pain, Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 2.0 (2.0 to 3.0) |
| Pain, Dose 3 (NH) | 2.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 2.0) |
| Swelling, Dose 1 | 4.0 (2.0 to 8.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.5) |
| Swelling, Dose 2 | 2.0 (1.0 to 3.0) | — | 3.0 (2.0 to 4.0) |
| Swelling, Dose 3 (NH) | — | 49.0 (49.0 to 49.0) | 1.5 (1.0 to 2.0) |
| Days | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Arthralgia, Dose 1 | 2.5 (1.0 to 4.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Arthralgia, Dose 2 | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 3.0) |
| Arthralgia, Dose 3 (NH) | 4.0 (3.0 to 4.0) | 2.0 (1.0 to 3.0) | 4.0 (1.0 to 4.0) |
| Fatigue, Dose 1 | 1.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Fatigue, Dose 2 | 2.0 (1.0 to 4.0) | 1.5 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Fatigue, Dose 3 (NH) | 1.0 (1.0 to 2.0) | 2.5 (1.0 to 3.5) | 2.0 (1.0 to 2.0) |
| Fever, Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.5) |
| Fever, Dose 2 | 2.0 (1.5 to 3.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 4.0) |
| Fever, Dose 3 (NH) | 1.0 (1.0 to 1.0) | — | — |
| Headache, Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Headache, Dose 2 | 2.0 (1.0 to 4.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Headache, Dose 3 (NH) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 1.0) | 2.0 (2.0 to 2.0) |
| Myalgia, Dose 1 | 1.5 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Myalgia, Dose 2 | 2.0 (1.0 to 4.0) | 1.5 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Myalgia, Dose 3 (NH) | 2.0 (1.0 to 3.0) | 3.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside of the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any= occurrence of the event regardless of intensity grade or relation to the study vaccination.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Any unsolicited AE (post Dose 1) | 2334 | 2149 | 2136 |
| Any unsolicited AE (post Dose 2) | 1570 | 824 | 1456 |
| Any unsolicited AE (post Dose 3) | 422 | 233 | 397 |
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of any SAE regardless of intensity grade or relation to study vaccination.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Any SAE (post Dose 1) | 541 | 280 | 268 |
| Any SAE (post Dose 2) | 497 | 239 | 229 |
| Any SAE (post Dose 3) | 179 | 75 | 73 |
pIMDs aredefined as a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any= occurrence of any pIMD regardless of intensity grade or relation to the study vaccination.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Any pIMDs (post Dose 1) | 39 | 27 | 19 |
| Any pIMDs (post Dose 2) | 39 | 19 | 14 |
| Any pIMDs (post Dose 3) | 13 | 8 | 10 |
Related SAEs that occur throughout the study are assessed. Related SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Number of Participants With Related SAEs | 12 | 8 | 12 |
Fatal SAEs that occur throughout the study are assessed. Fatal SAEs= Any SAEs leading to deaths.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Number of Participants With Fatal SAEs | 265 | 111 | 120 |
Related pIMD = pIMD assessed by the investigator as related to the study vaccination.
| Participants | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Number of Participants With Related pIMDs | 9 | 7 | 5 |
Collected over Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Group | 265/12,503 (2.1%) | 1,660/12,503 (13.3%) | 5,837/12,503 (46.7%) |
| RSV_1_dose Group | 111/6,226 (1.8%) | 799/6,226 (12.8%) | 3,663/6,226 (58.8%) |
| RSV_annual Group | 120/6,243 (1.9%) | 796/6,243 (12.8%) | 3,826/6,243 (61.3%) |
| Event | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| PneumoniaInfections and infestations | 80/12503 | 37/6226 | 34/6243 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 48/12503 | 38/6226 | 21/6243 |
| Atrial fibrillationCardiac disorders | 66/12503 | 22/6226 | 31/6243 |
| DeathGeneral disorders | 54/12503 | 18/6226 | 28/6243 |
| Myocardial infarctionCardiac disorders | 54/12503 | 17/6226 | 16/6243 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 38/12503 | 24/6226 | 18/6243 |
| Cerebrovascular accidentNervous system disorders | 46/12503 | 15/6226 | 22/6243 |
| SyncopeNervous system disorders | 21/12503 | 22/6226 | 13/6243 |
| COVID-19Infections and infestations | 34/12503 | 21/6226 | 19/6243 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 39/12503 | 20/6226 | 15/6243 |
| Event | Placebo Group | RSV_1_dose Group | RSV_annual Group |
|---|---|---|---|
| Injection site painGeneral disorders | 424/12503 | 1379/6226 | 1713/6243 |
| HeadacheNervous system disorders | 710/12503 | 594/6226 | 664/6243 |
| COVID-19Infections and infestations | 1178/12503 | 600/6226 | 601/6243 |
| FatigueGeneral disorders | 410/12503 | 394/6226 | 453/6243 |
| Injection site erythemaGeneral disorders | 56/12503 | 291/6226 | 449/6243 |
| Injection site swellingGeneral disorders | 38/12503 | 208/6226 | 347/6243 |
| MyalgiaMusculoskeletal and connective tissue disorders | 205/12503 | 228/6226 | 307/6243 |
| Upper respiratory tract infectionInfections and infestations | 526/12503 | 244/6226 | 243/6243 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 299/12503 | 226/6226 | 261/6243 |
| PyrexiaGeneral disorders | 85/12503 | 144/6226 | 197/6243 |
| Age, Continuous(YEARS) | RSVPreF3 Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 69.5 ± 6.5 | 69.6 ± 6.4 | 69.5 ± 6.5 |
| Sex: Female, Male(Participants) | RSVPreF3 Group | Placebo Group | Total |
|---|---|---|---|
| Female | 6489 | 6429 | 12918 |
| Male | 5980 | 6074 | 12054 |
| Race/Ethnicity, Customized(Participants) | RSVPreF3 Group | Placebo Group | Total |
|---|---|---|---|
| Asian | 953 | 956 | 1909 |
| Black or African American | 1064 | 1101 | 2165 |
| White | 9889 | 9936 | 19825 |
| All Other Races | 55 | 41 | 96 |
| Other | 508 | 469 | 977 |
Showing the first 100 of 277 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from May 2021 to primary completion in Apr 2022, 10 months.
Results were first posted in Aug 2023, 1 year 3 months after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 10 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →